Clinical Trials Logo

Clinical Trial Summary

This is a study of IBI362 in participants with overweight and obesity. The main purpose is to learn more about how IBI362 affects body weight. The study period including 4-8 weeks dose titration and 40-44 weeks maintain treatment and 12 weeks follow up.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04904913
Study type Interventional
Source Innovent Biologics (Suzhou) Co. Ltd.
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 8, 2021
Completion date January 31, 2024